AKRO - Akero Therapeutics, Inc.

$35.97

-0.76

(-2.07%)

Pre-Market: $37.50

1.53

(+4.25%)

Akero Therapeutics NASDAQ:AKRO Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Location: 601 Gateway Boulevard, Suite 350, California, 94080, United States | Website: www.akerotx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

2.864B

52 Wk Range

$17.86 - $58.40

Previous Close

$36.73

Open

$35.04

Day Range

$34.10 - 38.82

Volume

2,412,165

Avg Volume

1,426,165

Enterprise Value

2.217B

Cash

743.1M

Avg Qtr Burn

-57.53M

Short % of Float

7.84%

Insider Ownership

2.34%

Institutional Own.

93.41%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis , Cirrhosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis , Cirrhosis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.